
Sam M Pearson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4762144/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Application of Machine Learning to Assess Interindividual Variability in Rapid-Acting Insulin Responses After Subcutaneous Injection in People With Type 1 Diabetes. Canadian Journal of Diabetes, 2022, 46, 225-232.e2.	0.8	2
2	Risk factors associated with mortality in individuals with type 2 diabetes following an episode of severe hypoglycaemia. Results from a randomised controlled trial. Diabetes and Vascular Disease Research, 2022, 19, 147916412110674.	2.0	1
3	Glucose variability is associated with an adverse vascular profile but only in the presence of insulin resistance in individuals with type 1 diabetes: An observational study. Diabetes and Vascular Disease Research, 2022, 19, 147916412211032.	2.0	4
4	Body mass index, estimated glucose disposal rate and vascular complications in type 1 diabetes: Beyond glycated haemoglobin. Diabetic Medicine, 2021, 38, e14529.	2.3	24
5	Estimated glucose disposal rate as a candidate biomarker for thrombotic biomarkers in T1D: a pooled analysis. Journal of Endocrinological Investigation, 2021, 44, 2417-2426.	3.3	7
6	Reduction in cardiovascular mortality following severe hypoglycemia in individuals with type 2 diabetes: the role of a pragmatic and structured intervention. Cardiovascular Diabetology, 2021, 20, 18.	6.8	8
7	Aspirin, clopidogrel and prasugrel monotherapy in patients with type 2 diabetes mellitus: a double-blind randomised controlled trial of the effects on thrombotic markers and microRNA levels. Cardiovascular Diabetology, 2020, 19, 3.	6.8	31
8	Estimated glucose disposal rate demographics and clinical characteristics of young adults with type 1 diabetes mellitus: A cross-sectional pilot study. Diabetes and Vascular Disease Research, 2020, 17, 147916412095232.	2.0	11
9	Double diabetes: A distinct highâ€risk group?. Diabetes, Obesity and Metabolism, 2019, 21, 2609-2618.	4.4	65
10	>Oral Semaglutide In The Management Of Type 2 Diabetes: A Report On The Evidence To Date. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2019, Volume 12, 2515-2529.	2.4	20
11	The relative contribution of diurnal and nocturnal glucose exposures to HbA1c in type 1 diabetes males: a pooled analysis, Journal of Diabetes and Metabolic Disorders, 0 = 1	1.9	2